Company News
Aurobindo's CuraTeQ Biologics Announces Positive Phase 3 Results for Biosimilar
CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, announced positive top-line results from its Phase 3 trial for its Omalizumab biosimilar, BP11.
The Phase 3 study in chronic spontaneous urticaria
